Version 1
: Received: 7 August 2024 / Approved: 8 August 2024 / Online: 8 August 2024 (08:48:57 CEST)
How to cite:
Campanelli, G.; Waxner, N.; Parkhomovsky, N.; Mak, C. K.; Yin, J.-H.; Lin, S. J.-H.; Vanderstichel, R.; Yang, C.; Levenson, A. S. Identification of MTA1 as a New Molecular Marker for Canine Urothelial Carcinoma. Preprints2024, 2024080578. https://doi.org/10.20944/preprints202408.0578.v1
Campanelli, G.; Waxner, N.; Parkhomovsky, N.; Mak, C. K.; Yin, J.-H.; Lin, S. J.-H.; Vanderstichel, R.; Yang, C.; Levenson, A. S. Identification of MTA1 as a New Molecular Marker for Canine Urothelial Carcinoma. Preprints 2024, 2024080578. https://doi.org/10.20944/preprints202408.0578.v1
Campanelli, G.; Waxner, N.; Parkhomovsky, N.; Mak, C. K.; Yin, J.-H.; Lin, S. J.-H.; Vanderstichel, R.; Yang, C.; Levenson, A. S. Identification of MTA1 as a New Molecular Marker for Canine Urothelial Carcinoma. Preprints2024, 2024080578. https://doi.org/10.20944/preprints202408.0578.v1
APA Style
Campanelli, G., Waxner, N., Parkhomovsky, N., Mak, C. K., Yin, J. H., Lin, S. J. H., Vanderstichel, R., Yang, C., & Levenson, A. S. (2024). Identification of MTA1 as a New Molecular Marker for Canine Urothelial Carcinoma. Preprints. https://doi.org/10.20944/preprints202408.0578.v1
Chicago/Turabian Style
Campanelli, G., Ching Yang and Anait S Levenson. 2024 "Identification of MTA1 as a New Molecular Marker for Canine Urothelial Carcinoma" Preprints. https://doi.org/10.20944/preprints202408.0578.v1
Abstract
Although metastasis-associated protein 1 (MTA1) is known to play a role in cancer invasion and metastasis of various cancers, the clinical significance of its expression in canine urothelial carcinoma (UC) has not been explored. We sought to evaluate the expression of MTA1, cyclooxygenase 2 (COX2) and E-cadherin (E-cad) in association with clinicopathological parameters in clinical samples of canine UC. Here, we show that MTA1 and COX2 are overexpressed in canine UC samples compared to normal canine bladder samples, whereas E-cad levels are higher in normal bladder. The results demonstrated that MTA1 expression correlated with aggressive clinicopathological features such as high tumor-grade, muscular/vascular invasion, and metastasis. The expression of MTA1 differed in tumors depending on their localization, with the highest being in the urethra adjoining the prostate. Unexpectedly, higher E-cad levels were detected in metastatic tumor cells compared to primary tumor cells. Overall, these findings suggest that MTA1 may represent a key upstream effector tightly associated with COX2 and E-cad-mediated events in canine UC. Accordingly, MTA1 may be considered a feasible interceptive and therapeutic target for canine UC treatment.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
